Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomized, Two-treatment, Three-period, Three-sequence, Partial Replicate Oral Bioequivalence Study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited, India Comparing With That of PREVACID® (Containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc. USA, in Healthy, Adult, Human Subjects Under Fasting Conditions.

NCT01270308 is registered in ClinicalTrials.gov with Dr. Reddy's Laboratories Limited as lead sponsor.

NCT NCT01270308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01270308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomized, Two-treatment, Three-period, Three-sequence, Partial Replicate Oral Bioequivalence Study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited, India Comparing With That of PREVACID® (Containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc. USA, in Healthy, Adult, Human Subjects Under Fasting Conditions.
Lead sponsor
Dr. Reddy's Laboratories Limited
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2008
Completion date
December 31, 2008
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy